scholarly journals CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies—Immuno-oncology Advances Clinical Cancer Research

2015 ◽  
Vol 21 (12) ◽  
pp. 2657-2659 ◽  
Author(s):  
Dominik Wolf ◽  
Anna Maria Wolf
Keyword(s):  
Cancer Research ◽  
T Cells ◽  
Monoclonal Antibodies ◽  
Regulatory T Cells ◽  
Clinical Cancer Research ◽  
Clinical Cancer ◽  
20Th Anniversary

scholarly journals Clinical Cancer Research: The 20th Anniversary

2015 ◽  
Vol 21 (1) ◽  
pp. 3-3
Author(s):  
Kenneth C. Anderson ◽  
Jesse Potash
Keyword(s):  
Cancer Research ◽  
Clinical Cancer Research ◽  
Clinical Cancer ◽  
20Th Anniversary

Genomics and proteomics: Emerging technologies in clinical cancer research

2007 ◽  
Vol 61 (1) ◽  
pp. 1-25 ◽  
Author(s):  
Christine H. Chung ◽  
Shawn Levy ◽  
Pierre Chaurand ◽  
David P. Carbone
Keyword(s):  
Cancer Research ◽  
Emerging Technologies ◽  
Clinical Cancer Research ◽  
Clinical Cancer ◽  
Genomics And Proteomics

scholarly journals Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity

2018 ◽  
Vol 115 (4) ◽  
pp. E733-E742 ◽  
Author(s):  
Ronit Mazor ◽  
Emily M. King ◽  
Masanori Onda ◽  
Nicolas Cuburu ◽  
Selamawit Addissie ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
Monoclonal Antibodies ◽  
Antitumor Activity ◽  
Regulatory T Cells ◽  
Immune Tolerance ◽  
Checkpoint Inhibitors ◽  
Recombinant Immunotoxins ◽  
Antidrug Antibodies

Protein-based drugs are very active in treating cancer, but their efficacy can be limited by the formation of neutralizing antidrug antibodies (ADAs). Recombinant immunotoxins are proteins that are very effective in patients with leukemia, where immunity is suppressed, but induce ADAs, which compromise their activity, in patients with intact immunity. Here we induced a specific, durable, and transferable immune tolerance to recombinant immunotoxins by combining them with nanoparticles containing rapamycin (SVP-R). SVP-R mitigated the formation of inhibitory ADAs in naïve and sensitized mice, resulting in restoration of antitumor activity. The immune tolerance is mediated by colocalization of the SVP-R and immunotoxin to dendritic cells and macrophages in the spleen and is abrogated by depletion of regulatory T cells. Tolerance induced by SVPs was not blocked by checkpoint inhibitors or costimulatory agonist monoclonal antibodies that by themselves enhance ADA formation.

Sign in / Sign up

Export Citation Format

Share Document